马碧如 教授

研究范畴 <只提供英文版本>

1. Nasopharyngeal cancer: molecular targeted therapy and immunotherapy for metastatic/ recurrent disease, multi-modal treatment of locoregionally advanced disease.
2. Phase 1 clinical research and methodology, novel therapeutics for solid cancer.
3. Precision Oncology: development of predictive/ prognostic biomarkers for individualizing drug therapy and clinical trials for cancer patients.
4. Preclinical evaluation of novel drug therapies for GI and nasopharyngeal cancers, development of patient

履历概要 <只提供英文版本>

Professor Brigette Ma (MBBS (HONORS), MD (CUHK), FRACP, FHKCP, FHKAM (Medicine)) is currently Frances Lee Professor of Precision Oncology, Chief Director of the CUHK Phase I Clinical Trial Centre and Honorary Consultant at the Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong (CUHK). 

Professor Ma received her undergraduate degree with Honours at Monash University, Australia, and was awarded Fellow of the Royal Australasian College of Physicians, Fellow of Hong Kong College of Physicians, and Doctor of Medicine (CUHK). She underwent training in Medical Oncology at the Peter MacCallum Cancer Institute, Melbourne, and was Clinical Research Fellow (including Developmental Therapeutics) at the Princess Margaret Hospital, Toronto, Canada.

Professor Ma is dedicated to the development of innovative early phase clinical trials, novel immunotherapeutic combinations, and in advancing multimodal therapy for cancers of the head and neck. She is honoured to be endowed as Frances Lee Professor of Precision Oncology in 2025 and notably member of the European Society of Clinical Oncology (ESMO) Council since 2024. Professor Ma has a long history of service to influential oncological societies. She has served as Co-Chair of ESMO Asia congress, ESMO Targeted Anti-Cancer Therapy (TAT) Asia meeting and ESMO Advanced Course in Drug Development. She has also served in numerous international committees such as US-NCI Head and Neck Cancer Steering Committee – Clinical Trials Planning Group on Nasopharyngeal Cancer, Women in Cancer Research (WICR) of the American Association of Cancer Research, ASCO International Affairs Committee – Clinical Trials Workshop, the Chinese Society of Clinical Oncology and the NRG Head & Neck Committee.  In editorial service, she is Associate Editor of Oral Oncology and is member of the Editorial Boards of the Journal of Clinical Oncology, ESMO Open and ESMO Gastrointestinal Oncology.

Professor Ma has been regularly invited as Track Chair, speaker/ Keynote speaker and oral discussant at international conferences held by the ESMO, American Society of Clinical Oncology (ASCO), Chinese Society of Clinical Oncology (CSCO) and many others. As Study Chair of multiple co-operative group studies (e.g. NRG oncology, US National Cancer Institute, NCI, Cancer Therapy Evaluation Program), sponsored trials and investigator-initiated clinical trials, she has played a leading role in clinical research in nasopharyngeal cancer, colorectal cancer and Phase I Drug development, as well the development of clinical guidelines such as the ESMO Guideline for metastatic colorectal cancer and CSCO-ASCO guideline for nasopharyngeal carcinoma. She has published over 230 peer-reviewed papers, including book chapters and high impact journals such as Journal of Clinical Oncology, Lancet Oncology, New England Journal of medicine, Nature Medicine/ Nature Communications/ Nature Cancer.